Journal
IMMUNOLOGIC RESEARCH
Volume 39, Issue 1-3, Pages 79-93Publisher
HUMANA PRESS INC
DOI: 10.1007/s12026-007-0084-1
Keywords
TRAIL; neutrophil; PMN; BCG; Mycobacterium
Categories
Funding
- NATIONAL CANCER INSTITUTE [R01CA109446] Funding Source: NIH RePORTER
- NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R56AI034879, R01AI034879] Funding Source: NIH RePORTER
- Veterans Affairs [I01BX000513] Funding Source: NIH RePORTER
- NCI NIH HHS [CA109446] Funding Source: Medline
- NIAID NIH HHS [AI034879-19] Funding Source: Medline
- BLRD VA [I01 BX000513] Funding Source: Medline
Ask authors/readers for more resources
Bladder cancer is a huge economic burden on the healthcare system and is responsible for approximately 5% of all cancer deaths in humans. Mycobacterium bovis BCG-based therapy is the treatment of choice for superficial bladder cancer. Bacillus Calmette-Guerin (BCG) instillation in the bladder results in a massive local inflammatory response that has secondary antitumor properties. Recent studies have demonstrated that neutrophils present in the bladder after BCG instillation release large amounts of the apoptosis-inducing molecule TRAIL, as well as chemokines that recruit other immune cells, suggesting that neutrophils play a key role in the antitumor response to BCG therapy. This review discusses the impact of these findings on the understanding of the antitumor mechanisms underlying BCG-based immunotherapy for bladder cancer.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available